Company Overview and News

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.

Nektar Therapeutics Stock Is Risky But Offers Big Reward

2018-05-15 investorplace
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. Whether the underperformance is due to investors locking in profits or a lack of any news, the low trading volume suggests the stock could go anywhere from here.

UPDATE 3-U.S. state attorneys general sue Purdue Pharma over opioid epidemic

2018-05-15 reuters
NEW YORK (Reuters) - Six more U.S. states on Tuesday announced lawsuits against OxyContin maker Purdue Pharma LP, accusing the company of fueling a national opioid epidemic by deceptively marketing its prescription painkillers to generate billions of dollars in sales.

BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

2018-05-11 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) reported a loss of 18 cents per share for first-quarter 2018, which was narrower than the Zacks Consensus Estimate of a loss of 23 cents. However, in the year-ago quarter the company had recorded earnings of 87 cents per share.

Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

2018-05-10 zacks
Endo International plc (ENDP - Free Report) reported first-quarter 2018 results wherein both earnings and revenues surpassed estimates but declined year over year.

Endo International Plc (ENDP) Q1 2018 Results - Earnings Call Transcript

2018-05-08 seekingalpha
Good day, ladies and gentlemen, and welcome to the First Quarter 2018 Endo International plc Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this call is being recorded

BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?

2018-05-08 zacks
We expect BioDelivery Sciences International, Inc. (BDSI - Free Report) to beat estimates when it reports first-quarter 2018 results on May 10. In the last reported quarter, the company delivered a negative earnings surprise of 31.82%.

Aurobindo Pharma Bids $1.6 Billion for Novartis’ Generics Dermatology Business

2018-05-08 biospace
Swiss-based Novartis’ generics division, Sandoz, has been struggling in the face of intense pricing pressure. In the first quarter, Sandoz sales dropped 4 percent to $2.5 billion on a constant-currency basis. Excluding the U.S. sales, Sandoz sales grew 5 percent. Sandoz’s revenue dropped 17 percent in the fourth quarter of 2017, citing consolidation among buyers as the cause.

UPDATE 2-Endo posts Q1 beat, embraces branded drugs, injectables

2018-05-08 reuters
(Reuters) - Endo International Plc (ENDP.O) on Tuesday posted a quarterly profit that beat Wall Street estimates as the company makes good on plans to pivot to its injectables and branded drugs businesses, while remaining “laser-focused” on paying down long-term debt.

Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

2018-05-08 zacks
Investors in Endo International plc (ENDP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 11, 2018 $6.00 Call had some of the highest implied volatility of all equity options today.

BRIEF-Endo Posts Q1 Adj. Earnings $0.67/Shr From Continuing Operations

2018-05-08 reuters

Factors Likely to Impact Zillow (ZG) This Earnings Season

2018-05-07 zacks
Zillow Group Inc. (ZG - Free Report) is set to report first-quarter 2018 earnings on May 7. The company beat the Zack Consensus Estimate in three of the trailing four quarters, with an average positive earnings surprise of 43.92%.

UPDATE 1-Indivior's Q1 profit falls as blockbuster drug disappoints

2018-05-02 reuters
May 2 (Reuters) - Britain’s Indivior posted a 5 percent fall in quarterly profit on Wednesday, as its blockbuster treatment, Suboxone Film, lost market share in the U.S. due to stiff competition from generic versions.

Kentucky accuses J&J of contributing to opioid epidemic - Channel NewsAsia

2018-04-18 channelnewsasia
Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

UPDATE 1-Kentucky accuses J&J of contributing to opioid epidemic

2018-04-18 reuters
(Reuters) - Kentucky’s attorney general on Wednesday sued Johnson & Johnson(JNJ.N), accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...